Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the selected dose of aflibercept when it is
combined with R-CHOP treatment (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone
+/- intrathecal Methotrexate) administered every 2 weeks or every 3 weeks, in non Hodgkin
B-cell lymphoma, and to determine how the body handles aflibercept when it is administered
with R-CHOP.